Skip to main
ARTV
ARTV logo

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics Inc. is positively positioned due to its robust pipeline of off-the-shelf NK cell therapies, particularly the AlloNK candidate, which is designed to enhance the effectiveness of monoclonal antibodies in treating hematologic malignancies. The company has reported strong enrollment figures, with over a dozen patients in August and expectations for more than 20 by November, indicating a favorable safety profile and potential for durable clinical remissions. Additionally, the anticipated release of significant clinical response data in the first half of 2026 further supports a bullish outlook, suggesting the potential for substantial appreciation in the stock as these data sets are revealed.

Bears say

Artiva Biotherapeutics faces a negative outlook primarily due to the potential failure of its AlloNK therapy to demonstrate adequate efficacy and safety, with data expected in the first half of 2025 suggesting a decline in the probability of success to 10%. This failure could significantly affect the company's valuation, implying an approximate 25% downside to its base case scenario. Additionally, there are concerns about the overall viability of Artiva's NK cell therapy platform, which could hinder the company's ability to generate further successful clinical candidates.

ARTV has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Buy based on their latest research and market trends.

According to 4 analysts, ARTV has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.